Видео ютуба по тегу Aimmune

Brain Cast - Ep.5 Hacer lo correcto no siempre es fácil c/ Fabiana Lacerca, de Aimmune Therapeutics
Brain Cast - Ep.5 Hacer lo correcto no siempre es fácil c/ Fabiana Lacerca, de Aimmune Therapeutics
AIMT tender offer by Nestle
AIMT tender offer by Nestle
Генеральный директор Nestle о приобретении компанией Aimmune Therapeutics
Генеральный директор Nestle о приобретении компанией Aimmune Therapeutics
Aimmune Therapeutics confirms $2B Nestle acquisition
Aimmune Therapeutics confirms $2B Nestle acquisition
Aimmune Therapeutics big price action and possibility of a breakout - AIMT Stock
Aimmune Therapeutics big price action and possibility of a breakout - AIMT Stock
Nestle Pays $2 Billion To Secure Aimmune's Allergy Treatment
Nestle Pays $2 Billion To Secure Aimmune's Allergy Treatment
Nestle Pays $2 Billion To Secure Aimmune's Allergy Treatment
Nestle Pays $2 Billion To Secure Aimmune's Allergy Treatment
AIMT Stock | Aimmune Therapeutics Q2 2020 Earnings Call
AIMT Stock | Aimmune Therapeutics Q2 2020 Earnings Call
Market Movers : NESTLÉ : S'offre Aimmune Therapeutics, spécialisé dans l'allergie à l'arachide
Market Movers : NESTLÉ : S'offre Aimmune Therapeutics, spécialisé dans l'allergie à l'arachide
Aimmune™ Therapeutics - Allergy Immunology
Aimmune™ Therapeutics - Allergy Immunology
Молниеносный раунд Джима Крамера: Lockheed Martin — это покупка
Молниеносный раунд Джима Крамера: Lockheed Martin — это покупка
Aimmune Therapeutics - An oral study by Aimmune
Aimmune Therapeutics - An oral study by Aimmune
Latitude Founder's 16 year old daughter, Tessa Grosso testifying at the FDA panel for Aimmune.
Latitude Founder's 16 year old daughter, Tessa Grosso testifying at the FDA panel for Aimmune.
Watch CNBC's interview with Aimmune Therapeutics CEO on the company's peanut therapy
Watch CNBC's interview with Aimmune Therapeutics CEO on the company's peanut therapy
048 - Advisory Committee votes YES on Aimmune's Palforzia
048 - Advisory Committee votes YES on Aimmune's Palforzia
Biotech Stock On The Radar: Aimmune (AIMT stock) Awaits Adcom Test
Biotech Stock On The Radar: Aimmune (AIMT stock) Awaits Adcom Test
FDA panel recommends Aimmune's peanut allergy treatment
FDA panel recommends Aimmune's peanut allergy treatment
Aimmune Therapeutics' CEO and Office Environment - Q1 2019
Aimmune Therapeutics' CEO and Office Environment - Q1 2019
AIMMUNE APPEAL NL version
AIMMUNE APPEAL NL version
Former Aimmune Therapeutics CEO: Taking Stock in Allergies | Mad Money
Former Aimmune Therapeutics CEO: Taking Stock in Allergies | Mad Money
Aimmune signs Jayson Dallas on to succeed retiring CEO; Eduardo Bravo leaves TiGenix in final cha...
Aimmune signs Jayson Dallas on to succeed retiring CEO; Eduardo Bravo leaves TiGenix in final cha...
Working at Aimmune Therapeutics - May 2018
Working at Aimmune Therapeutics - May 2018
News of Note: Peanut Allergy Breakthrough
News of Note: Peanut Allergy Breakthrough
003 - Aimmune shows positive Phase 3 data for Peanut Allergy!
003 - Aimmune shows positive Phase 3 data for Peanut Allergy!
Peace of Mind
Peace of Mind